| Literature DB >> 30674530 |
Pauline J Beckmann1, Jon D Larson1, Alex T Larsson1, Jason P Ostergaard1, Sandra Wagner1, Eric P Rahrmann1,2, Ghaidan A Shamsan3, George M Otto1,4, Rory L Williams1,5, Jun Wang6, Catherine Lee6, Barbara R Tschida1, Paramita Das1, Adrian M Dubuc7, Branden S Moriarity1, Daniel Picard8,9, Xiaochong Wu10, Fausto J Rodriguez11, Quincy Rosemarie1,12, Ryan D Krebs1, Amy M Molan1,13, Addison M Demer1, Michelle M Frees1, Anthony E Rizzardi14, Stephen C Schmechel14,15, Charles G Eberhart16, Robert B Jenkins17, Robert J Wechsler-Reya6, David J Odde3, Annie Huang18, Michael D Taylor10, Aaron L Sarver1, David A Largaespada19.
Abstract
Medulloblastoma and central nervous system primitive neuroectodermal tumors (CNS-PNET) are aggressive, poorly differentiated brain tumors with limited effective therapies. Using Sleeping Beauty (SB) transposon mutagenesis, we identified novel genetic drivers of medulloblastoma and CNS-PNET. Cross-species gene expression analyses classified SB-driven tumors into distinct medulloblastoma and CNS-PNET subgroups, indicating they resemble human Sonic hedgehog and group 3 and 4 medulloblastoma and CNS neuroblastoma with FOXR2 activation. This represents the first genetically induced mouse model of CNS-PNET and a rare model of group 3 and 4 medulloblastoma. We identified several putative proto-oncogenes including Arhgap36, Megf10, and Foxr2. Genetic manipulation of these genes demonstrated a robust impact on tumorigenesis in vitro and in vivo. We also determined that FOXR2 interacts with N-MYC, increases C-MYC protein stability, and activates FAK/SRC signaling. Altogether, our study identified several promising therapeutic targets in medulloblastoma and CNS-PNET. SIGNIFICANCE: A transposon-induced mouse model identifies several novel genetic drivers and potential therapeutic targets in medulloblastoma and CNS-PNET. ©2019 American Association for Cancer Research.Entities:
Mesh:
Substances:
Year: 2019 PMID: 30674530 PMCID: PMC6397665 DOI: 10.1158/0008-5472.CAN-18-1261
Source DB: PubMed Journal: Cancer Res ISSN: 0008-5472 Impact factor: 12.701